title: Comparative transcriptomic analysis reveals the oncogenic fusion protein PAX3-FOXO1 globally alters mRNA and miRNA to enhance myoblast invasion.
abstract: Rhabdomyosarcoma, one of the most common childhood sarcomas, is comprised of two main subtypes, embryonal and alveolar (ARMS). ARMS, the more aggressive subtype, is primarily characterized by the t(2;13)(p35;p14) chromosomal translocation, which fuses two transcription factors, PAX3 and FOXO1 to generate the oncogenic fusion protein PAX3-FOXO1. Patients with PAX3-FOXO1-postitive tumors have a poor prognosis, in part due to the enhanced local invasive capacity of these cells, which leads to the increased metastatic potential for this tumor. Despite this knowledge, little is known about the role that the oncogenic fusion protein has in this increased invasive potential. In this report we use large-scale comparative transcriptomic analyses in physiologically relevant primary myoblasts to demonstrate that the presence of PAX3-FOXO1 is sufficient to alter the expression of 70 mRNA and 27 miRNA in a manner predicted to promote cellular invasion. In contrast the expression of PAX3 alters 60 mRNA and 23 miRNA in a manner predicted to inhibit invasion. We demonstrate that these alterations in mRNA and miRNA translate into changes in the invasive potential of primary myoblasts with PAX3-FOXO1 increasing invasion nearly 2-fold while PAX3 decreases invasion nearly 4-fold. Taken together, these results allow us to build off of previous reports and develop a more expansive molecular model by which the presence of PAX3-FOXO1 alters global gene regulatory networks to enhance the local invasiveness of cells. Further, the global nature of our observed changes highlights the fact that instead of focusing on a single-gene target, we must develop multi-faceted treatment regimens targeting multiple genes of a single oncogenic phenotype or multiple genes that target different oncogenic phenotypes for tumor progression.
authors.affiliation: Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Loupe
authors.affiliation: Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
authors.forename: P J
authors.initials: PJ
authors.lastname: Miller
authors.affiliation: Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
authors.forename: B P
authors.initials: BP
authors.lastname: Bonner
authors.affiliation: Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
authors.forename: E C
authors.initials: EC
authors.lastname: Maggi
authors.affiliation: Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
authors.forename: J
authors.initials: J
authors.lastname: Vijayaraghavan
authors.affiliation: Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
authors.forename: J S
authors.initials: JS
authors.lastname: Crabtree
authors.affiliation: Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
authors.forename: C M
authors.initials: CM
authors.lastname: Taylor
authors.affiliation: Department of Pediatrics and Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
authors.forename: J
authors.initials: J
authors.lastname: Zabaleta
authors.affiliation: Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
authors.forename: A D
authors.initials: AD
authors.lastname: Hollenbach